What are the oncological outcomes of patients with oropharyngeal carcinoma undergoing trans-oral robotic surgery (TORS)? An evaluation of TORS procedures from a single hospital in the UK.
DOI:
https://doi.org/10.22024/UniKent/03/ajpp.1388Resumen
Background: Trans-oral robotic surgery (TORS) is a relatively new, minimally invasive approach to treating head and neck cancer. The recent rise in head and neck cancers in younger patients, predominantly in oropharyngeal squamous cell carcinoma (OPSCC) due to the HPV virus spurs the need to examine how well TORS, alongside pre-existing therapies performs in cancer treatment.
Previous research has shown good survival outcomes in early disease stages, however, it is yet unclear how TORS contributes to treatment reflecting more diverse disease stages with the use of adjuvant treatments.
Methods: This case-series study sought to evaluate the oncological and QoL outcomes of TORS among 51 head and neck patients at a single centre in the UK. Several measures were aggregated and analysed which included: disease free survival (DFS), overall survival (OS), whether adjunct treatment was used, the extent of margin control, whether the TORS procedure was diagnostic or oncological resection, cancer stage, length of hospital stay, estimated blood loss, complications at review and patient perceived QoL as assessed by the MDADI questionnaire. The chi square test was performed to assess statistical significance between all variables, and the Pearson correlation was used to demonstrate the direction of resulting statistically significant associations.
Results: Patients ranged between stages T0-4a, N0-3b and received TORS with adjuvant treatment where clinically indicated. After an average follow-up of 18 months, overall survival (OS) was 98%, disease-free survival (DFS) 94.1% and patient QoL measures reflected good treatment response and functioning.
Conclusions: All consenting patients receiving TORS for a head and neck cancer were included in this study, thus patients showed ‘diverse’ characteristics – T0-4a, N0-3b, treated with TORS plus minus adjuvant therapy – CRT/CT/RT. Analysis showed good oncological outcomes with favourable MDADI scores 3.66, 75, which have been reflected by previous research. Overall TORS appears to provide a beneficial contribution to head and neck cancer treatment in the presence of good clinical decision making.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
AJPP requests that, as the creator(s)/author(s) of the manuscript you are submitting, that you assign certain rights to the manuscript to the AJPP in exchange for undertaking to publish the article in electronic form and, in general, to pursue its dissemination throughout the world. The rights the AJPP requests are:
- The right to publish the article in electronic form or in any other form it may choose that is in keeping with its role as a scholarly journal with the goal of disseminating the work as widely as possible;
- The right to be the sole publisher of the article for a period of 12 months;
- The right to make the article available to the public within a period of not more than 24 months, as determined by relevant journal staff of the AJPP;
- The right to grant republication rights to itself or others in print, electronic, or any other form, with any revenues accrued to be shared equally between the author(s) and the journal;
- The right to administer permission to use portions of the article as requested by others, seeking recompense when the AJPP sees it as warranted;
- The right to seek or take advantage of opportunities to have the article included in a database aimed at increasing awareness of it;
- As the author(s), the AJPP wishes you to retain the right to republish the article, with acknowledgement of the AJPP as the original publisher, in whole or in part, in any other pbulication of your own, including any anthology that you might edit with up to three others;
- As the author(s), the AJPP wishes you to retain the right to place the article on your personal Web page or respository of your university or institution. The AJPP askes that you include this notice: A fully edited, peer-reviewed version of this article was first published by the Advanced Journal of Professional Practice, <Year>, <Volume>, <Issue>, <Page Numbers>.
- You retain the right to unrestricted use of your paper for yourself or for your own teaching purposes.
BY AGREEING TO THE FOREGOING, YOU CONFIRM THAT THE MANUSCRIPT YOU ARE SUBMITTING HAS NOT BEEN PUBLISHED ELSEWHERE IN WHOLE OR IN PART, AND THAT NO AGREEMENT TO PUBLISH IS OUTSTANDING.
SHOULD THE ARTICLE CONTAIN MATERIAL WHICH REQUIRES WRITTEN PERMISSION FOR INCLUSION, YOU AGREE THAT IT IS YOUR OBLIGATION IN LAW TO IDENTIFY SUCH MATERIAL TO THE EDITOR OF THE AJPP AND TO OBTAIN SUCH PERMISSION. THE AJPP WILL NOT PAY ANY PERMISSION FEES. SHOULD THE AJPP BE OF THE OPINION THAT SUCH PERMISSION IS NECESSARY, IT WILL REQUIRE YOU TO PURSUE SUCH PERMISSSION PRIOR TO PUBLICATION.
AS AUTHOR(S), YOU WARRANT THAT THE ARTICLE BEING SUBMITTED IS ORIGINAL TO YOU.
Provided the foregoing terms are satisfactory, and that you are in agreement with them, please indicate your acceptance by checking the appropriate box and proceed with your submission.
